12月31日，康为世纪涨0.13%，成交额1565.46万元。两融数据显示，当日康为世纪获融资买入额55.38 万元，融资偿还116.74万元，融资净买入-61.36万元。截至12月31日，康为世纪融资融券余额合计 8755.65万元。 融资方面，康为世纪当日融资买入55.38万元。当前融资余额8755.65万元，占流通市值的9.56%，融资 余额超过近一年70%分位水平，处于较高位。 截至9月30日，康为世纪股东户数3905.00，较上期减少1.11%；人均流通股9729股，较上期增加1.13%。 2025年1月-9月，康为世纪实现营业收入1.40亿元，同比增长42.01%；归母净利润-7616.26万元，同比增 长20.37%。 分红方面，康为世纪A股上市后累计派现4863.19万元。 机构持仓方面，截止2025年9月30日，康为世纪十大流通股东中，融通健康产业灵活配置混合A/B （000727）位居第一大流通股东，持股260.00万股，相比上期减少100.00万股。圆信永丰医药健康A （006274）位居第五大流通股东，持股95.00万股，相比上期增加27.72万股。中欧时代先锋股票A （001938） ...

Core Viewpoint - On December 22, a total of 18 listed companies will have their restricted shares unlocked, with a total market value of approximately 102.97 billion yuan [1] Group 1: Unlocking Details - Walton Technology (Stock Code: 000920) will unlock 50.62 million shares from a private placement of A-shares [1] - China Hengtian Group (Stock Code: 600252) will unlock 2.36 million shares from equity incentive restrictions [1] - Huadian Energy (Stock Code: 600726) will unlock 4.73 billion shares from a private placement of A-shares [1] - AVIC Heavy Machinery (Stock Code: 600765) will unlock 2.68 million shares from equity incentive restrictions [1] - Nanjing Port (Stock Code: 002040) will unlock 151,800 shares from equity incentive restrictions [1] - Weichai Power (Stock Code: 000338) will unlock 23.48 million shares from equity incentive restrictions [1] - First Capital Securities (Stock Code: 601136) will unlock 2.25 billion shares from pre-issue share restrictions [1] - Anke Technology (Stock Code: 300370) will unlock 237 million shares from other restrictions [1] - Xinya Process (Stock Code: 002388) will unlock 346,550 shares from equity incentive restrictions [1] - Zhaoyi Innovation (Stock Code: 603986) will unlock 64,600 shares from equity incentive restrictions [1] - Ganli Pharmaceutical (Stock Code: 603087) will unlock 164,530 shares from equity incentive restrictions [1] - Yaxiang Co., Ltd. (Stock Code: 301220) will unlock 33.39 million shares with an extended lock-up period [1] - Mousse Co., Ltd. (Stock Code: 001323) will unlock 300 million shares with an extended lock-up period [1] - Sany Heavy Energy (Stock Code: 688349) will unlock 942 million shares [1] - Southern Power Technology (Stock Code: 688248) will unlock 336 million shares [1] - Jingwei Hengrun (Stock Code: 688326) will unlock 118,400 shares [1] - Kangwei Century (Stock Code: 688426) will unlock 434,200 shares [1] - Yuanjie Technology (Stock Code: 688498) will unlock 23.85 million shares [1]

Core Points - The company will have 434,236 shares listed for circulation on December 22, 2025, as part of its stock option incentive plan [1][2][4] - The total number of shares after the initial public offering (IPO) was 93,161,111, which has since increased to 112,493,716 shares due to stock option exercises and capital increases [2][3] Summary by Sections Listing Details - The type of stock listing is categorized as "other," with a total of 434,236 shares available for subscription through offline methods [1] - The circulation date for the listed shares is set for December 22, 2025 [1] Share Capital Changes - Following the IPO on October 25, 2022, the company had 93,161,111 shares, with 73,115,709 shares under limited circulation and 20,045,402 shares freely tradable [1] - On December 22, 2022, the first exercise of the stock option plan resulted in the issuance of 361,862 shares, raising the total share count to 93,522,973 [2] - A subsequent capital increase on May 16, 2023, led to a further increase in total shares to 112,227,568 [2] - The second exercise of the stock option plan on March 11, 2024, added 266,148 shares, bringing the total to 112,493,716 [3] Lock-up Period and Commitments - The shares being listed are subject to a lock-up period of 36 months from the exercise date, which began on December 22, 2022 [2] - Shareholders involved in the stock option exercise have committed to not reducing their holdings during this period and will adhere to the same reduction regulations as the company's directors and senior management after the lock-up expires [3]

Core Points - The company Jiangsu Kangwei Century Biotechnology Co., Ltd. is set to list 434,236 shares for trading on December 22, 2025, as part of its stock option incentive plan [2][4][11] - The shares being listed are part of the first exercise period of the 2021 stock option incentive plan, with a lock-up period of 36 months from the exercise date [5][7] - The total share capital of the company has increased from 93,161,111 shares at the time of its initial public offering to 112,493,716 shares currently, reflecting various capital increases and stock option exercises [6] Summary of Key Information - The total number of shares to be listed for trading is 434,236 [3][11] - The shares will be available for trading starting December 22, 2025 [4][11] - The shares are part of the stock option plan approved by the China Securities Regulatory Commission, which allowed the company to issue 23,290,278 shares during its IPO [4][5] - The company has undergone several changes in its total share capital since its IPO, including a capital increase through a bonus issue [6] - Shareholders of the newly listed shares have committed to a lock-up period of 36 months and will adhere to the same reduction regulations as the company's directors and senior management after the lock-up period [7][9]

Group 1 - The company Kangwei Century (SH 688426) announced that approximately 434,200 restricted shares will be unlocked and available for trading on December 22, 2025, representing 0.386% of the total share capital [1] - For the year 2024, the company's revenue will be entirely derived from the molecular diagnostics industry, accounting for 100.0% of its business [2] - As of the latest report, the market capitalization of Kangwei Century is 2.8 billion yuan [3]

证券代码：688426 证券简称：康为世纪 公告编号：2025-044 江苏康为世纪生物科技股份有限公司 关于首次公开发行前股票期权行权限售股上市流通的公告 ●本次股票上市类型为其他；股票认购方式为网下，上市股数为434,236股。 本次股票上市流通总数为434,236股。 ●本次股票上市流通日期为2025 年 12 月 22 日。 一、本次上市流通的限售股类型 2022 年 9 月 1 日，根据中国证券监督管理委员会《关于同意江苏康为世纪生 物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕2003 号）， 同意江苏康为世纪生物科技股份有限公司（以下简称"公司"）首次公开发行股票的 注册申请。公司首次向社会公开发行人民币普通股（A 股）23,290,278 股，并于 2022 年 10 月 25 日在上海证券交易所科创板上市交易。首次公开发行股票完成后， 公司总股本为 93,161,111 股。其中有限售条件流通股 73,115,709 股，无限售条件流 通股 20,045,402 股。具体情况详见公司于 2022 年 10 月 24 日在上海证券交易所网 站（www.sse.com.cn ...

中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏康 为世纪生物科技股份有限公司（以下简称"康为世纪"或"公司"）首次公开发 行股票并在科创板上市及后续持续督导保荐人，根据《中华人民共和国公司法》 《中华人民共和国证券法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证券交易所科创板股票上市规则》等有关法律法规和规 范性文件的要求，对公司首次公开发行前股票期权行权限售股上市流通的事项进 行了核查，核查情况及核查意见如下： 中信证券股份有限公司 关于江苏康为世纪生物科技股份有限公司 首次公开发行前股票期权行权限售股上市流通的核查意见 一、本次上市流通的限售股类型 2022 年 9 月 1 日，根据中国证券监督管理委员会《关于同意江苏康为世纪 生物科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕2003 号），同意江苏康为世纪生物科技股份有限公司（以下简称"公司"）首次公开 发行股票的注册申请。公司首次向社会公开发行人民币普通股（A 股）23,290,278 股，并于 2022 年 10 月 25 日在上海证券交易所科创板上市交易。首次公开发行 股票完成后 ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Views - The pharmaceutical and biotechnology sector saw a weekly increase of 2.67%, underperforming the Wind All A index (2.9%) but outperforming the CSI 300 index (1.64%). The raw material drug sector experienced a decline of 4.27%, while chemical preparations and pharmaceutical circulation products increased by 4.18% and 3.71%, respectively [3][8] - Recent policies in Shanghai and Beijing aim to support the high-quality development of the medical device industry, indicating a shift towards innovation and global competitiveness in this sector. The report suggests monitoring the transformation progress of leading companies in the medical device field [3][12] - Flu activity is on the rise, with the percentage of flu-like cases reported by sentinel hospitals in southern provinces reaching 7.8%, up from 6.8% the previous week, and higher than the same period in 2022 and 2024 [3][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector increased by 2.67% from November 24 to November 28, 2025, with raw material drugs declining by 4.27% and chemical preparations increasing by 4.18% [8][9] - Individual stock performances included significant gains for Haiwang Biological (38.2%), Yue Wannianqing (36.2%), and Guangji Pharmaceutical (31.7%), while *ST Changyao (-15.3%), Huitai Medical (-9.6%), and Kangwei Century (-8.8%) saw notable declines [11] Industry News and Key Company Announcements Important Industry Events - The report highlights the increase in flu-like illness percentages in both southern (7.8%) and northern (8.6%) provinces, indicating a significant rise in flu activity compared to previous years [11][12] Industry News - Significant approvals were noted, including the NMPA's approval of Xinmeiyue® for treating moderate to severe plaque psoriasis and the FDA's accelerated approval of Sibeprenlimab for IgAN treatment [12][14] Company Announcements - Notable announcements include the FDA approval of a generic injectable drug by Jianyou Co. and the successful completion of a Phase III trial for JS001sc, a subcutaneous PD-1 monoclonal antibody for non-small cell lung cancer [15][16]

Market Overview - The medical device sector increased by 1.13% on November 28, with Kangwei Century leading the gains [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] Top Performers - Kangwei Century (688426) closed at 27.86, up 5.17% with a trading volume of 18,500 lots and a transaction value of 50.42 million [1] - Mindray Medical (300760) closed at 204.01, up 3.93% with a trading volume of 117,800 lots and a transaction value of 2.378 billion [1] - Yingke Medical (300677) closed at 43.07, up 3.71% with a trading volume of 179,300 lots and a transaction value of 761 million [1] Underperformers - Weigao Orthopedics (688161) closed at 29.15, down 2.57% with a trading volume of 14,700 lots and a transaction value of 43.07 million [2] - Danna Biological (920009) closed at 81.75, down 2.21% with a trading volume of 8,252 lots and a transaction value of 67.67 million [2] - Zhonghong Medical (300981) closed at 14.21, down 2.07% with a trading volume of 86,200 lots and a transaction value of 122 million [2] Capital Flow - The medical device sector experienced a net outflow of 173 million from institutional investors, while retail investors saw a net inflow of 15.56 million [2] - The top stocks by net inflow from retail investors included Mindray Medical and Hotgen Biotech, while Zhendong Medical and Haier Biomedical saw significant net outflows [3]

Group 1 - The core viewpoint of the news is that Jiangsu Kangwei Century Biotechnology Co., Ltd. has seen a stock price increase of 5.13%, reaching 27.85 CNY per share, with a total market capitalization of 3.133 billion CNY [1] - The company was established on September 3, 2010, and went public on October 25, 2022, focusing on the research, production, and sales of molecular detection products, with 89.14% of its revenue coming from product sales [1] - The trading volume for the stock was 39.9693 million CNY, with a turnover rate of 3.88% [1] Group 2 - Among the top ten circulating shareholders, the fund under Yuanxin Yongfeng has increased its holdings in Kangwei Century by 277,200 shares, now holding a total of 950,000 shares, which represents 2.5% of the circulating shares [2] - The Yuanxin Yongfeng Medical Health A fund has achieved a year-to-date return of 35.33%, ranking 1785 out of 8127 in its category [2] - The fund has a total scale of 387 million CNY and has generated a floating profit of approximately 1.292 million CNY from its recent investment [2]